Market Cap 170.05M
Revenue (ttm) 0.00
Net Income (ttm) -19.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 155,400
Avg Vol 176,684
Day's Range N/A - N/A
Shares Out 25.46M
Stochastic %K 14%
Beta -0.27
Analysts Strong Sell
Price Target $18.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, Suite 275, Fort Lee, United States
NVDAMillionaire
NVDAMillionaire Sep. 8 at 7:16 PM
$NVCT Really good write-up that perfectly summarizes NVCT's present situation. So if you want to bring your NVCT knowledge up to date or just discover NVCT, this is required reading. https://beyondspx.com/quote/NVCT/analysis/nuvectis-pharma-s-high-stakes-pivot-nxp900-takes-center-stage-in-precision-oncology-nasdaq-nvct
0 · Reply
biospeculator
biospeculator Sep. 5 at 2:38 PM
$NVCT New Truffle Pig analysis is out. Their timing and pps predictions to date have been too optimistic. However, their thesis of value for the NXP900 drug IF proven in trials are imo very interesting. I am long.
1 · Reply
WallStWireAds
WallStWireAds Sep. 4 at 11:31 AM
$NVCT https://caplynx.io/2MLQZfm
0 · Reply
tasha655
tasha655 Sep. 2 at 5:38 PM
0 · Reply
tasha655
tasha655 Aug. 26 at 5:08 PM
$NVCT this will be $10
0 · Reply
biospeculator
biospeculator Aug. 24 at 2:15 PM
$NVCT From a technical standpoint, I clearly see a wave II completion in a typical abc pattern. IF so then we are about to enter wave III which should equal 2x wave one. Wave I was $4.5-$11.5 or $7. Therefore, under Elliot wave theory wave III should be $14 or a target of $20. Looking at the 3 year chart, we see that target is exactly the previous high. MY TARGET FOR THIS MOVE IS $20! glta
0 · Reply
BioTrade2
BioTrade2 Aug. 22 at 2:28 AM
$NVCT https://www.youtube.com/watch?v=eE65NbLS6BE
0 · Reply
BioTrade2
BioTrade2 Aug. 22 at 1:37 AM
$NVCT Dr. Neil Carragher https://www.youtube.com/watch?v=eE65NbLS6BE&ab_channel=whereswallaceTV
0 · Reply
topstockalerts
topstockalerts Aug. 21 at 1:40 PM
$NVCT she wants to move higher..
2 · Reply
UNLV
UNLV Aug. 21 at 1:20 PM
$NVCT biggest pumper sometimes 10 daily post...$30 by June, $100 eoy and $200 by summer. Endlessly pounding Truffle Pig and now this!
1 · Reply
Latest News on NVCT
Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


NVDAMillionaire
NVDAMillionaire Sep. 8 at 7:16 PM
$NVCT Really good write-up that perfectly summarizes NVCT's present situation. So if you want to bring your NVCT knowledge up to date or just discover NVCT, this is required reading. https://beyondspx.com/quote/NVCT/analysis/nuvectis-pharma-s-high-stakes-pivot-nxp900-takes-center-stage-in-precision-oncology-nasdaq-nvct
0 · Reply
biospeculator
biospeculator Sep. 5 at 2:38 PM
$NVCT New Truffle Pig analysis is out. Their timing and pps predictions to date have been too optimistic. However, their thesis of value for the NXP900 drug IF proven in trials are imo very interesting. I am long.
1 · Reply
WallStWireAds
WallStWireAds Sep. 4 at 11:31 AM
$NVCT https://caplynx.io/2MLQZfm
0 · Reply
tasha655
tasha655 Sep. 2 at 5:38 PM
0 · Reply
tasha655
tasha655 Aug. 26 at 5:08 PM
$NVCT this will be $10
0 · Reply
biospeculator
biospeculator Aug. 24 at 2:15 PM
$NVCT From a technical standpoint, I clearly see a wave II completion in a typical abc pattern. IF so then we are about to enter wave III which should equal 2x wave one. Wave I was $4.5-$11.5 or $7. Therefore, under Elliot wave theory wave III should be $14 or a target of $20. Looking at the 3 year chart, we see that target is exactly the previous high. MY TARGET FOR THIS MOVE IS $20! glta
0 · Reply
BioTrade2
BioTrade2 Aug. 22 at 2:28 AM
$NVCT https://www.youtube.com/watch?v=eE65NbLS6BE
0 · Reply
BioTrade2
BioTrade2 Aug. 22 at 1:37 AM
$NVCT Dr. Neil Carragher https://www.youtube.com/watch?v=eE65NbLS6BE&ab_channel=whereswallaceTV
0 · Reply
topstockalerts
topstockalerts Aug. 21 at 1:40 PM
$NVCT she wants to move higher..
2 · Reply
UNLV
UNLV Aug. 21 at 1:20 PM
$NVCT biggest pumper sometimes 10 daily post...$30 by June, $100 eoy and $200 by summer. Endlessly pounding Truffle Pig and now this!
1 · Reply
BioTrade2
BioTrade2 Aug. 19 at 7:05 PM
$NVCT this setback (nxp800) and data desert for the next 9-12 months should hopefully get all the pumpers out. Remember when biosensai and labradar kept predicting $20 next week and 200 next yr. Do not listen to anyone who predicts share prices or sets unrealistic targets. Now we wait to see 900 data. It’s all or nothing. Bet accordingly. If the 900 update shows any doubt, this will crash hard. GL
0 · Reply
BioSensai
BioSensai Aug. 19 at 4:15 PM
$NVCT $2 stock people. Do not believe permabulls here. it will be over a year until data and expect multiple dilution rounds took them 12 months to enroll 9 patients in NXP-800...
2 · Reply
Value_Runner
Value_Runner Aug. 18 at 6:36 PM
$NVCT where did @BioSensai go? This ticker is quiet without him.
0 · Reply
UNLV
UNLV Aug. 15 at 2:28 PM
$NVCT I'm big Nuvectis Pharma tailing insider action especially Charles continued buying. $OPEN got my action tailing Paul Tudor Jones and Anthony Pompliano don't just follow the money follow...follow the smart money
0 · Reply
biospeculator
biospeculator Aug. 12 at 7:55 PM
$NVCT An institution with more money and better due diligence than myself paid $8-$8.5 per share for 1.6M shares just before the release of the NXP800 results because they were afraid of paying more if the results were good. We now have the opportunity to pay 20% less. Hmmmmm.....I did!
0 · Reply
F4651110
F4651110 Aug. 12 at 3:43 PM
$NVCT anyone joined the call, any feedback?
2 · Reply
biospeculator
biospeculator Aug. 12 at 2:05 PM
$NVCT Phase 1b begins. New Truffle Pig's thesis is that institutional and hedge fund buying has begun and will continue despite the low float, I agree with this thesis. Simply put, the institutions are under invested. With an upside of 20x(my opinion) or 30x-40x (Truffle Pig) we have plenty of upside during this accumulation period, imo. GLTA
1 · Reply
AmateurHourGR
AmateurHourGR Aug. 12 at 10:59 AM
$NVCT https://nuvectis.com/press-release-view/
0 · Reply
UNLV
UNLV Aug. 8 at 7:05 PM
$NVCT 800 failure widening quarterly loss double previous quarter and pessimism around 12M dilution alongside market makers taking out Stop/Loss orders $6 gives best entry since February offering. WAITING for better entry will get you PUNKED and buying higher
0 · Reply
BioTrade2
BioTrade2 Aug. 8 at 6:09 PM
$NVCT “this better not be the next XAIR” -Charles. That’s what he is probably thinking right now.
2 · Reply
WallStWireAds
WallStWireAds Aug. 7 at 6:40 PM
0 · Reply
WallStWireAds
WallStWireAds Aug. 7 at 6:40 PM
0 · Reply